Alprazolam and Diazepam in the Treatment of Generalized Anxiety

  title={Alprazolam and Diazepam in the Treatment of Generalized Anxiety},
  author={Robert {\'E}lie and Yves Lamontagne},
  journal={Journal of Clinical Psychopharmacology},
In a 4-week double-blind study comparing alprazolam with diazepam treatments, 48 outpatients suffering from mild to moderate generalized anxiety were evaluated after a 5-day placebo washout, and then after 1, 2, and 4 weeks of treatment. The optimal therapeutic doses without excessive sedation averaged 2 mg for alprazolam and 15.8 mg for diazepam. Results from the Hamilton Anxiety Rating Scale, the Clinical Global Impression Scale, a behavior checklist questionnaire, and a symptomatic patients… Expand
Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder
Both mexazolam and alprazolam showed a significant anxiolytic effect and were well tolerated in the treatment of GAD, making it an effective pharmacotherapeutic alternative in the Treatment of G AD. Expand
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine. Expand
Treatment effects of alprazolam and imipramine: Physiological versus subjective changes in patients with generalized anxiety disorder
Though the physiological changes associated with alprazolam treatment were consistent with changes in symptom reports, treatment with imipramine produced a desynchrony: patients reported significant decreases in cardiovascular symptoms and muscle tension in spite of the fact that heart rate, blood pressure, and electromyographic activity increased. Expand
Clinical uses of benzodiazepines. Focus on: benzodiazepines and anxiety disorders
Benzodiazepines have proven very effective in panic disorder, generalized anxiety and, even if to a lower degree, in social phobia, and role in obsessive compulsive disorder and post traumatic stress disorder is not as strong but these medications may be useful for several patients with those diseases. Expand
History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders.
The following paper details the pharmacodynamic history of treating anxiety and also updates the reader as to the newer GABA-based approaches mentioned above. Expand
Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal
A critical appraisal of the current use and role of BZDs in psychiatric disorders and their disadvantages is provided, with specific emphasis on anxiety and affective disorders, sleep disorders, alcohol withdrawal, violent and aggressive behaviours in psychoses, and neuroleptic-induced disorders. Expand
Benzodiazepines and anxiety disorders: a review for the practicing physician
BZDs remain a mainstay in the treatment of anxiety, as both monotherapy and adjunctive therapy, and factors to consider prior to prescribing a BZD include the patient's diagnosis, as well as drug characteristics, including the potential for interactions with other drugs, the risk of dependence and withdrawal, and the required frequency of dosing. Expand
The diagnosis and treatment of generalized anxiety disorder.
The treatment of GAD with CBT and drugs is evidence-based and has a good chance of improving the manifestations of the disorder. Expand
Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal.
Results suggest that abecarnil and alprazolam may have therapeutic potential for treatment of ethanol withdrawal-induced anxiety-like symptoms. Expand
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders
Recommendations for the pharmacological treatment of anxiety and obsessive-compulsive disorders are presented, based on available randomized, placebo- or comparator-controlled clinical studies, and SSRIs are recommended for the first line and MAOIs, moclobemide and benzodiazepines as second line. Expand